Trevor Angell, MD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
AddressBMT B11
Off Campus
Los Angeles CA 90089-9113
Phone+1 323 442 6179
vCardDownload vCard
    Other Positions
    Title(s)Associate Medical Director of Thyroid Center

    Collapse Overview 
    Collapse Overview
    Trevor E Angell, MD is an Associate Professor of Clinical Medicine in the Department of Medicine’s division of endocrinology and diabetes at Keck School of Medicine of USC. Dr. Angell is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interest is the diagnosis and treatment of thyroid diseases. He is recognized for clinical expertise in thyroid nodules, thyroid cancer, and thyroid disorders during pregnancy. He is nationally known for research into thyroid nodule evaluation and molecular testing of thyroid nodules.
    Dr. Angell has published articles in JAMA Surgery, Thyroid, the Journal of Clinical Endocrinology and Metabolism, and Current Opinion in Endocrinology and Diabetes, including original research and invited reviews. He has received funding for his research predicting thyroid cancer in patients with thyroid nodules from the Thyroid Cancer Survivors' Association (American Thyroid Association Research Grant). He is on the editorial board of the top endocrinology journals, including Thyroid and the Journal of Clinical Endocrinology and Metabolism. He is currently a member of the American Thyroid Association Thyroid Nodule Guidelines Taskforce and a member of the International Thyroid Oncology Group.
    After finishing his clinical and research training at the Keck School of Medicine and the Los Angeles General Medical Center, Dr. Angell became an instructor in medicine at the Brigham and Women’s Hospital and Harvard Medical School, performing patient care, residents and fellow teaching, and research. Dr. Angell returned to USC and joined the faculty at the Keck School of Medicine in 2018.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Evaluation of YouTube As A Source For Graves' Disease Information: Is High-Quality Guideline-Based Information Available? OTO Open. 2024 Jan-Mar; 8(1):e118. Ayo-Ajibola O, Davis RJ, Theriault C, Lamb C, Choe D, Lin ME, Angell TE, Kwon DI. PMID: 38504881; PMCID: PMC10949313.
      View in: PubMed   Mentions:
    2. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci. JAMA Otolaryngol Head Neck Surg. 2024 Mar 01; 150(3):209-214. Mao YV, Hughes EG, Steinmetz D, Troob S, Kim J, Tseng CH, Fishbein GA, Sajed DP, Livhits MJ, Yeh MW, Lee D, Angell TE, Wu JX. PMID: 38270925; PMCID: PMC10811588.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Clinical Features and Outcomes of Myxedema Coma in Patients Hospitalized for Hypothyroidism: Analysis of the United States National Inpatient Sample. Thyroid. 2024 Feb 28. Chen DH, Hurtado CR, Chang P, Zakher M, Angell TE. PMID: 38279788.
      View in: PubMed   Mentions:    Fields:    
    4. Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report. Case Rep Ophthalmol. 2024 Jan-Dec; 15(1):115-121. Mehta P, Angell T, LeTran V, Lin M, Nguyen A, Zhang-Nunes S. PMID: 38318283; PMCID: PMC10843176.
      View in: PubMed   Mentions:
    5. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830. Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. PMID: 38027216; PMCID: PMC10643762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis. AACE Clin Case Rep. 2023 Sep-Oct; 9(5):162-165. Chen DH, Lenz HJ, Lechner MG, Angell TE. PMID: 37736314; PMCID: PMC10509378.
      View in: PubMed   Mentions:
    7. Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Sci Transl Med. 2023 05 17; 15(696):eadg0675. Lechner MG, Zhou Z, Hoang AT, Huang N, Ortega J, Scott LN, Chen HC, Patel AY, Yakhshi-Tafti R, Kim K, Hugo W, Famini P, Drakaki A, Ribas A, Angell TE, Su MA. PMID: 37196065; PMCID: PMC10227862.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    8. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis. J Clin Endocrinol Metab. 2023 05 17; 108(6):1526-1532. Nasr CE, Andrioli M, Endo M, Harrell RM, Livhits MJ, Osakwe I, Polavarapu P, Siperstein A, Wei S, Zheng X, Jiang R, Hao Y, Huang JIN, Klopper JP, Kloos RT, Kennedy G, Angell TE. PMID: 36470585; PMCID: PMC10188305.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    9. Malignancy Risk of Thyroid Nodules That Are Not Classifiable by the American Thyroid Association Ultrasound Risk Stratification System: A Systematic Review and Meta-Analysis. Thyroid. 2023 05; 33(5):593-602. Kwon D, Kulich M, Mack WJ, Monedero RM, Joyo E, Angell TE. PMID: 36855336; PMCID: PMC10171963.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Finding the Balance on Extent of Initial Thyroidectomy for Low-Risk Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2022 12 17; 108(1):e7-e8. Angell TE, Kwon DI. PMID: 36137000.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier. Thyroid. 2022 09; 32(9):1069-1076. Randolph GW, Sosa JA, Hao Y, Angell TE, Shonka DC, LiVolsi VA, Ladenson PW, Blevins TC, Duh QY, Ghossein R, Harrell M, Patel KN, Shanik MH, Traweek ST, Walsh PS, Yeh MW, Abdelhamid Ahmed AH, Ho AS, Wong RJ, Klopper JP, Huang J, Kennedy GC, Kloos RT, Sadow PM. PMID: 35793115; PMCID: PMC9526471.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    12. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 08 15; 209(4):696-709. Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. PMID: 35817515; PMCID: PMC9378719.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    13. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. Thyroid. 2022 05; 32(5):496-504. Mosaferi T, Tsai K, Sovich S, Wilhalme H, Kathuria-Prakash N, Praw SS, Drakaki A, Angell TE, Lechner MG. PMID: 35199588; PMCID: PMC9145255.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    14. Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment. Front Endocrinol (Lausanne). 2022; 13:824226. Ahmadi S, Pappa T, Kang AS, Coleman AK, Landa I, Marqusee E, Kim M, Angell TE, Alexander EK. PMID: 35222281; PMCID: PMC8873520.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis. Endocr Pract. 2022 May; 28(5):502-508. Silva de Morais N, Angell TE, Ahmadi S, Alexander EK, Dos Santos Teixeira PF, Marqusee E. PMID: 35091101.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study. Clin Breast Cancer. 2022 06; 22(4):e558-e566. Kathuria-Prakash N, Antrim L, Hornstein N, Sun AW, Kang IM, Baclig NV, Angell TE, Lechner MG, Wald-Dickler N, In GK. PMID: 35027318; PMCID: PMC8677421.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    17. Hypoglycemic episodes predict length of stay in patients with acute burns. J Crit Care. 2021 08; 64:68-73. Pham CH, Vrouwe SQ, Tsai K, Ding L, Collier ZJ, Grote AC, Angell TE, Garner WL, Gillenwater TJ, Yenikomshian HA. PMID: 33794469; PMCID: PMC8527897.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract. 2021 Feb; 27(2):90-94. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, Su MA, Lechner MG. PMID: 33551317; PMCID: PMC7831810.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    19. Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection. J Med Virol. 2021 05; 93(5):2645-2653. Rosen HR, O'Connell C, Nadim MK, DeClerck B, Sheibani S, DePasquale E, Sanossian N, Blodget E, Blodget E, Angell T. PMID: 33090515; PMCID: PMC7675751.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    20. Hürthle cell lesions of the thyroid: Progress made and challenges remaining. Cancer Cytopathol. 2021 05; 129(5):347-362. Wong KS, Angell TE, Barletta JA, Krane JF. PMID: 33108684.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    21. Analysis of the strategy of LT4 prescribing and TSH monitoring for thyroid carcinoma after lobectomy. Ann Transl Med. 2020 Oct; 8(19):1238. Wang Z, Angell TE, Sun W, Qin Y, He L, Dong W, Zhang D, Zhang T, Shao L, Lv C, Zhang P, Guan H, Zhang H. PMID: 33178770; PMCID: PMC7607107.
      View in: PubMed   Mentions: 1  
    22. Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis. Oncologist. 2021 02; 26(2):e251-e260. Lechner MG, Bernardo AC, Lampe A, Praw SS, Tam SH, Angell TE. PMID: 32864832; PMCID: PMC7873343.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines. Ann Surg Oncol. 2021 Jan; 28(1):484-491. Kuo LE, Angell TE, Pandian TK, Moore AL, Alexander EK, Barletta JA, Gawande AA, Lorch JH, Marqusee E, Moore FD, Nehs MA, Doherty GM, Cho NL. PMID: 32583197.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. Letter to the Editor: Use of Molecular Diagnostic Tests in Thyroid Nodules with Hürthle Cell-Dominant Cytology. Thyroid. 2020 09; 30(9):1390-1392. Endo M, Nabhan F, Angell TE, Harrell RM, Nasr C, Wei S, Sipos JA. PMID: 32228149.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    25. Insights From a Real-World Study of Molecular Test Performance for Indeterminate Thyroid Nodules. J Clin Endocrinol Metab. 2020 04 01; 105(4). Angell TE. PMID: 31761942.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules. J Clin Endocrinol Metab. 2019 11 01; 104(11):5665-5672. Angell TE, Maurer R, Wang Z, Kim MI, Alexander CA, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Krane JF, Marqusee E, Moore FD, Nehs MA, Larsen PR, Alexander EK. PMID: 31310316.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    27. GROWTH HAPPENS: HOW CAN INCREASING THYROID NODULE SIZE BE USED TO PREDICT MALIGNANCY? Endocr Pract. 2019 10; 25(10):1074-1076. Angell TE. PMID: 31613160.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Treatment of Differentiated Thyroid Carcinomas. Surg Pathol Clin. 2019 Dec; 12(4):931-942. Lechner MG, Praw SS, Angell TE. PMID: 31672299.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules. Thyroid. 2019 11; 29(11):1594-1605. Goldner WS, Angell TE, McAdoo SL, Babiarz J, Sadow PM, Nabhan FA, Nasr C, Kloos RT. PMID: 31469053; PMCID: PMC6864764.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    30. Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples. Front Endocrinol (Lausanne). 2019; 10:612. Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG. PMID: 31572297; PMCID: PMC6749016.
      View in: PubMed   Mentions: 15     Fields:    
    31. Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults. Thyroid. 2019 08; 29(8):1097-1104. Cherella CE, Angell TE, Richman DM, Frates MC, Benson CB, Moore FD, Barletta JA, Hollowell M, Smith JR, Alexander EK, Cibas ES, Wassner AJ. PMID: 31298618; PMCID: PMC6707031.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    32. Getting more out of molecular testing for indeterminate thyroid nodules. Cancer Cytopathol. 2019 Sep; 127(9):555-556. Angell TE. PMID: 31237737.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Thyroid Nodules and Thyroid Cancer in the Pregnant Woman. Endocrinol Metab Clin North Am. 2019 09; 48(3):557-567. Angell TE, Alexander EK. PMID: 31345523.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. Cancer Immunol Res. 2019 07; 7(7):1214-1220. Ma C, Hodi FS, Giobbie-Hurder A, Wang X, Zhou J, Zhang A, Zhou Y, Mao F, Angell TE, Andrews CP, Hu J, Barroso-Sousa R, Kaiser UB, Tolaney SM, Min L. PMID: 31088848; PMCID: PMC6606328.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    35. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules. Thyroid. 2019 05; 29(5):650-656. Angell TE, Heller HT, Cibas ES, Barletta JA, Kim MI, Krane JF, Marqusee E. PMID: 30803388.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    36. The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer. J Endocr Soc. 2019 Apr 01; 3(4):791-800. Silva de Morais N, Stuart J, Guan H, Wang Z, Cibas ES, Frates MC, Benson CB, Cho NL, Nehs MA, Alexander CA, Marqusee E, Kim MI, Lorch JH, Barletta JA, Angell TE, Alexander EK. PMID: 30963137; PMCID: PMC6446886.
      View in: PubMed   Mentions: 26  
    37. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis. Endocr Pathol. 2019 Mar; 30(1):43-48. Wong KS, Higgins SE, Marqusee E, Nehs MA, Angell T, Barletta JA. PMID: 30565013.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    38. Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery. Ann Surg Oncol. 2019 Jan; 26(1):93-97. Lindeman BM, Nehs MA, Angell TE, Alexander EK, Gawande AA, Moore FD, Doherty GM, Cho NL. PMID: 30341576.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    39. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg. 2018 09 01; 153(9):817-824. Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW. PMID: 29799911; PMCID: PMC6583881.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    40. Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children. J Clin Endocrinol Metab. 2018 09 01; 103(9):3557-3565. Cherella CE, Feldman HA, Hollowell M, Richman DM, Cibas ES, Smith JR, Angell TE, Wang Z, Alexander EK, Wassner AJ. PMID: 29982665; PMCID: PMC6126895.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    41. POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS. Endocr Pract. 2018 Jun; 24(6):512-516. Angell TE, Van Benschoten O, Cohen DA, Haas AV, Alexander EK, Marqusee E. PMID: 29624097.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients ≥70 Years Old. Thyroid. 2018 04; 28(4):465-471. Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell TE. PMID: 29608439.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    43. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. Thyroid. 2018 04; 28(4):445-453. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. PMID: 29652597.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    44. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. Thyroid. 2018 04; 28(4):437-444. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. PMID: 29652599.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    45. Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule. Ann Surg Oncol. 2018 May; 25(5):1410-1417. Angell TE, Vyas CM, Barletta JA, Cibas ES, Cho NL, Doherty GM, Gawande AA, Howitt BE, Krane JF, Marqusee E, Strickland KC, Alexander EK, Moore FD, Nehs MA. PMID: 29520656.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). Endocr Pathol. 2018 Mar; 29(1):68-74. Strickland KC, Eszlinger M, Paschke R, Angell TE, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA. PMID: 29396809.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    47. Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. J Clin Endocrinol Metab. 2017 12 01; 102(12):4642-4647. Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD, Nehs MA, Zavacki AM, Larsen PR, Alexander EK. PMID: 29040691.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    48. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes Dis. 2018 Mar; 5(1):46-48. Angell TE, Min L, Wieczorek TJ, Hodi FS. PMID: 29619406; PMCID: PMC5879785.
      View in: PubMed   Mentions: 24  
    49. RAS-positive thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2017 Oct; 24(5):372-376. Angell TE. PMID: 28639967.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience. Cancer Cytopathol. 2017 Nov; 125(11):854-864. Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF. PMID: 28902465.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    51. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas. Endocr Pathol. 2017 Jun; 28(2):171-176. Wong KS, Strickland KC, Angell TE, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA. PMID: 28271380.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    52. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations. Thyroid. 2017 04; 27(4):506-511. Paulson VA, Shivdasani P, Angell TE, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA. PMID: 28114855.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    53. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Cancer Cytopathol. 2017 05; 125(5):313-322. Baca SC, Wong KS, Strickland KC, Heller HT, Kim MI, Barletta JA, Cibas ES, Krane JF, Marqusee E, Angell TE. PMID: 28152275; PMCID: PMC5484344.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    54. Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4938-4944. Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell TE, Alexander EK. PMID: 27689252; PMCID: PMC5155682.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    55. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. Thyroid. 2016 07; 26(7):911-5. Wong KS, Angell TE, Strickland KC, Alexander EK, Cibas ES, Krane JF, Barletta JA. PMID: 27219469.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    56. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent. Thyroid. 2016 Mar; 26(3):381-9. Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL. PMID: 26756227; PMCID: PMC4790214.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    57. Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study. BMC Med. 2016 Jan 27; 14:11. Medici M, Liu X, Kwong N, Angell TE, Marqusee E, Kim MI, Alexander EK. PMID: 26817603; PMCID: PMC4730757.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    58. HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. AACE Clin Case Rep. 2016; 2(4):e370-e373. Minkovsky A, Lee MN, Dowlatshahi M, Angell TE, Mahrokhian LS, Petrides AK, Melanson SE, Marqusee E, Woodmansee WW. PMID: 27917400; PMCID: PMC5134919.
      View in: PubMed   Mentions: 11  
    59. Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis. Thyroid. 2016 Feb; 26(2):256-61. Liu X, Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Larsen PR, Cho NL, Nehs MA, Ruan DT, Gawande A, Moore F, Barletta J, Krane JF, Cibas ES, Yang T, Alexander EK. PMID: 26563459; PMCID: PMC4754507.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    60. The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. J Clin Endocrinol Metab. 2015 Dec; 100(12):4434-40. Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta JA, Kim MI, Larsen PR, Alexander EK. PMID: 26465395; PMCID: PMC4667162.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    61. Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up. J Clin Endocrinol Metab. 2015 Nov; 100(11):E1477-83. Angell TE, Frates MC, Medici M, Liu X, Kwong N, Cibas ES, Kim MI, Marqusee E. PMID: 26353010; PMCID: PMC4702458.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    62. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015 Aug 07; 13:184. Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD, Alexander EK. PMID: 26253102; PMCID: PMC4528713.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    63. Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol. 2015 Sep; 94(9):1603-4. Angell TE, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S. PMID: 26048244.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. PMID: 25343237.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    65. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. PMID: 25294906; PMCID: PMC4252612.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    66. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. PMID: 24955518; PMCID: PMC4148060.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    67. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. PMID: 24697314.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    Trevor's Networks
    Concepts (182)
    Derived automatically from this person's publications.
    Co-Authors (42)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department